Antibiotics

Escalating usage and more drug choices are putting more people at risk.

This approach can help with clinical outcomes and mortality, but resistance is not as well defined.

Ongoing education and proven outcomes need to aid this form of testing.

Social identity plays an important role in how antimicrobial stewards see their roles and influences how they communicated with prescribers.

Letters to legislators call for increased funding to address ongoing crisis.

Spero Therapeutics expects to submit a new drug application this year for Tebipenem HBr, the first oral carbapenem for treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).

Filmmaker Bill Mudge has released his new documentary, Beating Superbugs: Can We Win? It looks at emerging technologies designed to develop new therapies to combat antibiotic resistance (ABR).

New drugs likely won’t meet resistance challenges ahead, authors say.

Melinta Therapeutics’ oritavancin therapy is indicated for treatment of acute bacterial skin and skin structure infections (ABSSSI) in adult patients.

While the world’s focus remains on COVID-19, beyond this ongoing crisis lingers another that requires leadership, innovation, and collaboration from policy makers, the health care community, and the private sector.

A pair of experts assess literature on the means of interpreting hospitalized patient antibiotic resistance through machine learning.

An assessment of a comparative study between leading options for a burdensome infection.

The IDSA representative discusses advances made in recent years, and how foundational guidance could be set by the FDA with input from specialists.

We asked a simple question to our IDWeek experts: has COVID-19 taken attention away from any greater infectious disease issues?

As the threat of infection with multidrug-resistant gram-negative organisms persists, new antimicrobials are a welcome addition to the armamentarium of infectious diseases clinicians.

Why it may be more prudent for prescribing clinicians to assume viral, rather than bacterial, infection while awaiting test results in presenting pediatric cases.

New data suggest collaboration between hospital prescribers and stewardship teams is still not perfected.

New data show the pandemic, and a lack of efficacious therapies, did harm to 4 years' worth of stewardship.

The urgent care setting is a prime target for antimicrobial stewardship efforts as it becomes an increasingly prevalent form of healthcare delivery.

Sulopenem was superior to ciprofloxacin for the treatment of uncomplicated urinary tract infections.

The composition of the gut microbiome is easily disrupted by antibiotics, leaving the host susceptible to further infection or other disturbance of gut flora that can lead to both short- and long-term deleterious effects.

Antimicrobial-resistant infections, in particular those caused by gram-negative pathogens that also produce extended spectrum β-lactamases (ESBL), represent a growing threat across the globe as investigators race to develop novel therapeutics

Antibiotics are compared to surgery for appendicitis in light of patient concerns about hospitalization and hospital concerns about resources during COVID-19.

Dr. Debra Goff describes the rush to "Just in Case" prescribing of antibiotics early in the COVID-19 pandemic, when less was known about the clinical course of the disease.

The time to first antibiotic dose is an important step of this new program, however it may require an audit after review according to a new study.

About 1 in 5 patients with bloodstream infections received discordant empirical antibiotic therapy, increasing their risk of mortality independent of sepsis or septic shock, a new study found.